Global contract development and manufacturing organization (CDMO) Recipharm has opened a new analytical lab in Bengaluru, India to enhance its global testing capabilities for nitrosamines, extractables and leachables, and elemental impurity testing.

Fully cGMP/cGLP compliant, the 5,000 square foot lab will expand Recipharm’s existing analytical capabilities and provide support for biotech and pharma customers in their research and development of oral solids, drug delivery, inhalation, vaccines and injectables.

The investment in the new lab responds to the increasing demand for a trusted testing services partner. Filling a critical gap in the market, the lab will ensure product safety, regulatory compliance, consumer protection and patient well-being are considered in each project.

With new testing capabilities, Recipharm now provides customers with accurate and reliable testing services, method development and validation, and batch release testing of excipients, drug substance, drug product and container closure systems.

“The launch of Recipharm’s new analytical lab marks a new era in cutting-edge laboratory techniques for us as a Group,” said Gregor Kawaletz, head of business unit OSD at Recipharm. “This key milestone represents our commitment to staying at the forefront of analytical technologies, ensuring that safety and quality of pharmaceutical and biopharmaceutical products is at the core of everything we do. With innovative methodologies and unmatched expertise, this new lab makes Recipharm a trusted partner for those seeking reliable solutions to ensure product safety and compliance for their projects. We are excited about the opportunities this lab will bring and look forward to continuing to service our clients with analytical testing excellence and reliability.”

Recipharm continues to focus its efforts on expanding both its facilities and its workforce, with 30 new and experienced research scientists commencing work at the lab which is now fully operational.